|
Insights on the Oral Proteins and Peptides Global Market to 2032 - Key Drivers and Challenges
Friday, March 25, 2022
DUBLIN, March 21, 2022 /PRNewswire/ -- The "Oral Proteins and Peptides Market by Target Disease Indication, Type of Molecule, Technology Platforms, Biological Target, Mechanism of Action, Key Players, and Key Geographical Regions, 2022-2032" report has been added to ResearchAndMarkets.com's offering.
http://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
This report provides an extensive study on the current market landscape of orally administrable protein / peptide-based therapeutics, along with the future market potential. In addition, it provides an in-depth analysis, highlighting the market landscape of technology providers engaged in this domain.
Since the approval of the first protein / peptide-based therapy (recombinant human insulin) in 1982, there has been a substantial increase in the R&D initiatives focused on such products. Earlier, majority of the biologics were administered subcutaneously. However, with the technological advancements in delivery formulations, oral delivery of therapeutic interventions has gained significant traction, prompting stakeholders to leverage their expertise in the development of orally administrable proteins / peptides.
Interestingly, in the last decade, three orally administered protein / peptide-based therapies have been approved, namely Mycapssa (2020), Trulance (2017) and Linzess (2012) across different geographies. The rising popularity of this upcoming class of therapeutics has led to the reformulation / development of oral protein / peptide-based product candidates for the treatment of a myriad of disease indications across multiple therapeutic areas (including but not limited to metabolic disorders, gastrointestinal disorders, autoimmune disorders). It is worth mentioning that oral administration is a favorable route for delivery of drugs to pediatric and geriatric patients, primarily due to its non-invasive nature. In addition, the ease of administration associated with the oral delivery method has been demonstrated increase treatment adherence to as well as reduce the risk of non-compliance.
Protein / peptide-based therapeutics have revolutionized the pharmaceutical landscape, this can be attributed to the wide applications and target specific nature of such interventions. However, oral formulations of protein / peptide-based drugs have been associated with several drawbacks, including poor bioavailability and drug decomposition in the gastrointestinal tract. In order to mitigate the aforementioned challenges, players engaged in this domain have conducted extensive research for the development of novel biological targets, thereby, strengthening their research pipelines.
In addition, this segment of the industry has also attracted the attention of both private and public sector investors / investment funds, which have extended financial support to the initiatives of developers. It is also worth mentioning that, over the last few years, the market has witnessed an active participation of big pharma players and substantial partnership activity. Given the ongoing research and development initiatives and an encouraging response to the already marketed drugs, the oral protein / peptide therapies market is poised to witness significant growth over the coming decade.
Amongst other elements, the report features:
-- A detailed assessment of the current market landscape of oral proteins /
peptides, providing information on the developer, type of molecule
(protein or peptide), phase of development (commercial, clinical,
preclinical or discovery stage), target therapeutic area(s), biological
target, mechanism of action, number of amino acids and affiliated
technology platform. In addition, the chapter includes information on
drug developer(s), highlighting their year of establishment, company
size, and location of headquarters.
-- A detailed competitiveness analysis of oral protein / peptide therapy
developers based on several relevant parameters, such as supplier power
(in terms of years of experience and employee count), pipeline strength
and phase of development.
-- An in-depth analysis of the product pipeline and developer companies,
featuring three schematic representations; these include [A] a four
dimensional grid analysis, representing the distribution of oral
proteins / peptides (on the basis of the type of molecule) across
various target therapeutic areas and stages of development, [B] a logo
landscape of companies involved in the development of oral protein /
peptide-based drugs, distributed on the basis of phase of development of
pipeline candidates and size of developer companies (small, mid-sized
and large companies), and [C] a schematic world map representation,
highlighting the most active geographies, in terms of the presence of
various industry players engaged in the development of oral proteins /
peptides.
-- A detailed analysis identifying the key opinion leaders (KOLs),
featuring a 2X2 analysis to assess the relative experience of certain
KOLs, who were shortlisted based on their contributions (in terms of
involvement in various clinical studies) in this field.
-- An overview of the current market landscape of technology platforms
available for the development of oral protein / peptide therapeutics,
along with information on their developer, type of platform, compatible
API types, target therapeutic area, dosage form and status of
development of products. In addition, the chapter includes information
on technology developer(s), highlighting their year of their
establishment, company size and location of headquarters.
-- A 2X2 matrix, comparing product competitiveness and supplier power of
the technology platforms that are presently being used for the
development of oral proteins / peptides. The analysis takes into
consideration several parameters, such as year of establishment, company
size and development activity (number of drugs in both preclinical /
clinical stages of development).
-- An analysis of the investments made at various stages of development,
such as seed financing, venture capital financing, debt financing,
grants / awards, capital raised from IPOs and subsequent offerings, by
companies that are engaged in this field.
-- An analysis of the partnerships that have been established in the
domain, over the last five years, covering licensing agreements,
acquisitions, R&D agreements, product commercialization agreements,
clinical trial agreements and other relevant deals.
-- A detailed review of more than 300 peer-reviewed, scientific articles
related to research on oral protein / peptides, which have been
published since 2017.
-- A detailed analysis of completed, ongoing and planned clinical studies,
based on several relevant parameters, such as trial registration year,
enrolled patient population, trial status, trial phase, type of sponsor
/ collaborator, patient segment, target therapeutic area, study design,
most active players (industry and non-industry) and regional
distribution of trials.
-- An in-depth analysis of the patents related to oral protein / peptides,
filed / granted since 2017, based on several relevant parameters, such
as publication year, geographical location / patent jurisdiction, legal
status, CPC symbols, emerging focus areas, type of applicant and leading
players (by number of patents). In addition, it features a patent
valuation analysis which evaluates the qualitative and quantitative
aspects of the patents.
-- An analysis of big pharma players engaged in this domain, featuring a
spider-web analysis based on several relevant parameters, such as number
of pipeline candidates, partnership agreements and publications.
-- A detailed case study on protein / peptide contract manufacturing,
featuring a list of over 140 CMOs that are currently offering contract
manufacturing services for such products / product candidates.
-- An elaborate discussion on the various commercialization and lifecycle
management strategies that have been adopted by drug developers engaged
in this domain across different stages of therapy development, including
prior to drug launch, at / during drug launch and post-marketing stage.
-- A discussion on affiliated trends, key drivers and challenges, under a
SWOT framework. The analysis features a Harvey ball analysis,
highlighting the relative effect of each SWOT parameter on the overall
oral proteins / peptides market.
Key Questions Answered
-- Who are the key players involved in the development of oral protein /
peptide therapeutics?
-- Which technologies are leveraged the most by oral protein / peptide
therapy developers?
-- Who are the key opinion leaders in this domain?
-- Which geographies are the most active in conducting clinical trials
focused on oral protein / peptide therapeutics?
-- Which companies have received the maximum funding for the development
for oral protein / peptide therapeutics? Who are the most prominent
investors?
-- Which partnership models are commonly adopted by industry stakeholders
in the development of oral protein / peptide therapeutics?
-- Which organizations have filed the maximum number of patents in this
field?
-- How is the current and future market opportunity likely to be
distributed across key market segments?
Key Topics Covered:
1. PREFACE
2. EXECUTIVE SUMMARY
3. INTRODUCTION
4. MARKET OVERVIEW
5. COMPANY COMPETITIVENESS ANALYSIS
6. KEY INSIGHTS
7. KOL ANALYSIS
8. KEY THERAPEUTIC AREAS
9. MARKETED AND LATE-STAGE DRUG PROFILES
9.1. Chapter Overview
9.2. Linzess / Constella / Linaclotide (Ironwood Pharmaceuticals)
9.2.1. Drug Overview
9.2.2. History of Development
9.2.3. Mechanism of Action
9.2.4. Dosage Form, Treatment Regimen and Price
9.2.5. Manufacturing Information
9.2.6. Current Status of Development
9.2.7. Clinical Studies
9.2.8. Key Clinical Trial Results
9.2.9. Historical Sales
9.2.10. Developer Overview
9.3. Trulance / Plecanatide (Synergy Pharmaceuticals)
9.4. TBRIAT / Oral Calcitonin (Tarsa Therapeutics / Enteris BioPharma)
9.5. Mycapssa / (Chiasma Pharma)
9.6. ALLN-177 (Allena Pharmaceuticals)
9.7. INN-202 (9 Meters Biopharma)
9.8. ORMD-0801 (Oramed Pharmaceuticals)
9.9. IN-105 (Biocon)
9.10. Oral HDV Insulin (Diasome Pharmaceuticals)
10. CASE STUDIES: MINIRIN, SANDIMMUNE AND SOLLPURA
10.1. Chapter Overview
10.2. Minirin / DDAVP (Ferring Pharmaceuticals)
10.2.1. Drug Overview
10.2.2. History of Development
10.2.3. Chemical Structure and Mechanism of Action
10.2.4. Dosage Form, Treatment Regimen and Price
10.2.5. Patent Portfolio
10.2.6. Competitive Landscape
10.3. Sandimmune / Neoral (Novartis)
10.4. Sollpura / Liprotamase (Anthera Pharmaceuticals)
11. ORAL PROTEIN / PEPTIDE DEVELOPMENT TECHNOLOGIES: MARKET LANDSCAPE
11.1. Chapter Overview
11.2. Oral Protein / Peptide Development Technologies: Market Landscape
11.2.1. Analysis by Type of Technology
11.2.2. Analysis by Compatible API Types
11.2.3. Analysis by Target Therapeutic Area
11.2.4. Analysis by Dosage Form
11.2.5. Analysis by Status of Development of Products
11.3. Oral Protein / Peptide Development Technologies: Developer Landscape
11.3.1 Analysis by Year of Establishment
11.3.2. Analysis by Company Size
11.3.3 Analysis by Location of Headquarters
11.3.4. Analysis by Company Size and Location of Headquarters
12. PRODUCT COMPETITIVENESS ANALYSIS
12.1. Chapter Overview
12.2. Scope and Methodology
12.3. Product Competitiveness Analysis: Key Technologies
13. ORAL DRUG DELIVERY TECHNOLOGY PLATFORMS
13.1. Chapter Overview
13.2. Oral Drug Delivery: List of Technology Platforms
13.3. Technology Profiles
13.3.1. AxcessT Oral Drug Delivery Technology (Proxima Concepts)
13.3.1.1. Developer Overview
13.3.1.2. Technology Overview
13.3.1.3. Drug Delivery Mechanism
13.3.1.4. Key Advantages
13.3.1.5. Oral Proteins / Peptides Pipeline
13.3.1.6. Collaborations
13.3.2. EligenT Technology (Emisphere Technologies)
13.3.3. Entera Technology (Entera Bio)
13.3.4. NTRA Oral Delivery Technology (Nutrinia)
13.3.5. Peptelligence Technology (Enteris BioPharma)
13.3.6. Protein Oral Delivery (PODT) Technology (Oramed Pharmaceuticals)
13.3.7. Transient Permeability Enhancer (TPE) Technology (Chiasma Pharma)
13.3.8. Uroguanylin Analogue Technology (Synergy Pharmaceuticals)
14. FUNDING AND INVESTMENT ANALYSIS
15. RECENT COLLABORATIONS
16. PUBLICATION ANALYSIS
17. CLINICAL TRIAL ANALYSIS
18. PATENT ANALYSIS
19. BIG PHARMA ANALYSIS
20. MARKET FORECAST AND OPPORTUNITY ANALYSIS
21. CASE STUDY: PROTEIN / PEPTIDE MANUFACTURING
22. KEY COMMERCIALIZATION / LIFECYCLE MANAGEMENT STRATEGIES
23. SWOT ANALYSIS
24. CONCLUSION
25. EXECUTIVE INSIGHTS
26. APPENDIX 1: RECENT DEVELOPMENTS
27. APPENDIX 2: TABULATED DATA
28. APPENDIX 3: LIST OF COMPANIES
For more information about this report visit https://www.researchandmarkets.com/r/vtq1mr
Media Contact:
Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
View original content:https://www.prnewswire.com/news-releases/insights-on-the-oral-proteins-and-peptides-global-market-to-2032---key-drivers-and-challenges-301506667.html
SOURCE Research and Markets
|
|
|
|
|
|
 |
Skunk Works® and XTEND Expand Joint All Domain Command and Control for Advanced Mission Execution | Jan 22, 2026
|
|
Sup AI Sets New Benchmark Record with 52.15% on Humanity's Last Exam | Jan 22, 2026
|
|
Weekly Recap: 11 Tech Press Releases You Need to See | Jan 22, 2026
|
|
Trigent Partners with WeWork India to Expand its GCC Footprint | Jan 22, 2026
|
|
DEADLINE ANNOUNCED FOR 2026 NEW TOP-LEVEL DOMAIN APPLICATIONS | Jan 22, 2026
|
|
Exia Labs Brings Keystone to the U.S. Navy via DIU's Blue Object Management Challenge | Jan 22, 2026
|
|
Genpact Named a Leader in ISG Provider Lens(TM) 2025 for Insurance GCCs and Agentic AI Services | Jan 22, 2026
|
|
Marketing Evolution Announces New Investment Led by Insight Partners to Power AI-Ready Marketing Data for the Agentic Era | Jan 22, 2026
|
|
Glasswall Brings Defense-Level File Sanitization to Every Government Agency and Business Using Microsoft 365 | Jan 22, 2026
|
|
Altair HyperWorks 2026 Delivers Design and Simulation at Scale with AI | Jan 22, 2026
|
|
|
|
